The National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), has awarded a $23,579,701 Cooperative Agreement to Ensysce Biosciences, Inc. to support the clinical development of PF614-MPAR, an opioid product with oral overdose protection. The key objectives of this project are to continue the clinical development of PF614-MPAR, a combination product of a trypsin-activated abuse protection (TAAP) oxycodone prodrug and a trypsin inhibitor...
This federal Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $4,710,576.00 to Mebias Discovery Inc. to develop a new chemical entity, MEB-1170, as a maintenance medication for the treatment of opioid use disorder (OUD). The project aims to complete preclinical studies in rodents and non-human primates to evaluate the efficacy of MEB-1170 in reducing fentanyl self-administration and its safety...
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $3,138,031.00 to Sparian Biosciences Inc. (doing business as Palion Therapeutics) to conduct clinical development of SBS-147, a first-in-class non-opioid oral arylepoxamide agonist for the treatment of acute and chronic pain. The award will fund a Phase 1 SAD/MAD clinical trial to characterize the safety, tolerability, and...
This Cooperative Agreement award, valued at $11,872,077.00, was granted by the National Institute on Drug Abuse (NIDA) under the federal Drug Use and Addiction Research Programs (CFDA 93.279). The funding supports the development of SBS-226, a novel non-addictive chemical entity that acts as a mu-opioid receptor (MOR) agonist and delta-opioid receptor (DOR) antagonist, for the treatment of opioid use disorder (OUD). The primary recipient, Sparian Biosciences Inc. (doing business as Palion...
This Project Grant award of $399,483, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to leverage synergy between artificial intelligence (AI) and DNA-encoded library (DEL) technologies to identify novel polypharmacological therapeutics for substance use disorders (SUDs). The key objectives are to generate multivalent compounds that can simultaneously target and restore imbalances in the opioid, dopaminergic, and...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $798,828 to Dark Matter Therapeutics, Inc. to discover novel small molecule therapeutics for the safe and effective treatment of opioid use disorder (OUD). The funded project will leverage artificial intelligence (AI) to develop an integrated drug discovery platform called M3.AI that combines target-based and phenotype-based methodologies. The goal...
This $399,884 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to identify small molecule compounds that can bind to the GPR26 receptor, which is believed to be a novel target for treating opioid use disorders. The research strategy involves using DNA-encoded library (DEL) screening technology to efficiently test over 125 million novel compounds and identify high-affinity binders to GPR26 that can...
This Project Grant award of $847,000 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to evaluate the therapeutic potential of neuropeptide S receptor 1 (NPSR1) agonism for reducing opioid self-administration and relapse in preclinical animal models. The research team at the University of Tennessee Health Science Center will leverage pharmacological tools to investigate NPSR1 as a novel target for treating...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding the development of a novel epigenetic regulator as a potential treatment for opioid use disorder (OUD). The grantee, Epivario Inc., a for-profit biotechnology research organization, will screen a new class of ACSS2 inhibitors and evaluate their efficacy in preclinical animal models of OUD. Specifically, the $275,253 award will support...
This Cooperative Agreement award, totaling $2,104,389.00, was provided by the National Institute on Drug Abuse (NIDA) under the federal Drug Use and Addiction Research Programs (CFDA 93.279). The award supports research to evaluate the use of oxytocin, an FDA-approved drug, to treat opioid-induced respiratory depression and prevent opioid overdose lethality. Specifically, the research will: 1) identify the optimal dose, route of administration, and redosing requirements for oxytocin to reverse...